{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:43:29Z","timestamp":1793609009752,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The R337H is a <jats:italic>TP53<\/jats:italic> germline pathogenic variant that has been associated with several types of cancers, including breast cancer. Our main objective was to determine the frequency of the R337H variant in sporadic breast cancer patients from Paran\u00e1 state, South Brazil, its association with prognosis and its impact in genomic instability. The genotyping of 805 breast cancer tissues revealed a genotypic and allelic frequency of the R337H variant of 2.36% and 1.18%, respectively. In these R337H+ cases a lower mean age at diagnosis was observed when compared to the R337H-cases. Array-CGH analysis showed that R337H+ patients presented a higher number of copy number alterations (CNAs), compared to the R337H\u2212. These CNAs affected genes and miRNAs that regulate critical cancer signaling pathways; a number of these genes were associated with survival after querying the KMplot database. Furthermore, homozygous (R337H+\/R337H+) fibroblasts presented increased levels of copy number variants when compared to heterozygous or R337H\u2212 cells. In conclusion, the R337H variant may contribute to 2.36% of the breast cancer cases without family cancer history in Paran\u00e1. Among other mechanisms, R337H increases the level of genomic instability, as evidenced by a higher number of CNAs in the R337H+ cases compared to the R337H\u2212.<\/jats:p>","DOI":"10.1038\/s41598-020-73282-y","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T10:04:27Z","timestamp":1601978667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Frequency of the TP53 R337H variant in sporadic breast cancer and its impact on genomic instability"],"prefix":"10.1038","volume":"10","author":[{"given":"Carolina","family":"Mathias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9fanne","family":"Bortoletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana","family":"Centa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heloisa","family":"Komechen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubens S.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline S.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Sebasti\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00edcero A.","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson W. S.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Prando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonald C.","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iglenir J.","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciane R.","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enilze M. F. S.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"issue":"1","key":"73282_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/nsb730","volume":"9","author":"EL DiGiammarino","year":"2002","unstructured":"DiGiammarino, E. L. et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat. Struct. Biol. 9(1), 12\u201326 (2002).","journal-title":"Nat. Struct. Biol."},{"key":"73282_CR2","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.1073\/pnas.161479898","volume":"98","author":"RC Ribeiro","year":"2001","unstructured":"Ribeiro, R. C. et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc. Natl. Acad. Sci. U. S. A. 98, 9330\u20139335 (2001).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"73282_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/jmg.2004.030551","volume":"43","author":"BC Figueiredo","year":"2006","unstructured":"Figueiredo, B. C. et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J. Med. Genet. 43, 91\u201396 (2006).","journal-title":"J. Med. Genet."},{"issue":"11","key":"73282_CR4","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3390\/cancers11111804","volume":"11","author":"TEJ Costa","year":"2019","unstructured":"Costa, T. E. J. et al. Penetrance of the TP53 R337H mutation and pediatric adrenocortical carcinoma incidence associated with environmental influences in a 12-year observational cohort in Southern Brazil. Cancers (Basel). 11(11), 1804\u20131820 (2019).","journal-title":"Cancers (Basel)."},{"key":"73282_CR5","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2012.46.3711","volume":"31","author":"G Cust\u00f3dio","year":"2013","unstructured":"Cust\u00f3dio, G. et al. Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J. Clin. Oncol. 31, 2619\u20132626 (2013).","journal-title":"J. Clin. Oncol."},{"key":"73282_CR6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1590\/S0004-27302004000500009","volume":"48","author":"EM Pinto","year":"2004","unstructured":"Pinto, E. M. et al. Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq. Bras. Endocrinol. Metabol. 48, 647\u2013650 (2004).","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"issue":"3","key":"73282_CR7","doi-asserted-by":"publisher","first-page":"e18015","DOI":"10.1371\/journal.pone.0018015","volume":"6","author":"G Custodio","year":"2011","unstructured":"Custodio, G. et al. Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil. PLoS ONE 6(3), e18015 (2011).","journal-title":"PLoS ONE"},{"key":"73282_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2156-10-5","volume":"10","author":"S Garritano","year":"2009","unstructured":"Garritano, S. et al. Determining the effectiveness of High Resolution Melting analysis for SNP genotyping and mutation scanning at the TP53 locus. BMC Genet. 10, 1\u201312 (2009).","journal-title":"BMC Genet."},{"key":"73282_CR9","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1002\/cncr.25826","volume":"117","author":"AL Seidinger","year":"2011","unstructured":"Seidinger, A. L. et al. Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in Southeast Brazil. Cancer 117, 2228\u20132235 (2011).","journal-title":"Cancer"},{"key":"73282_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0140356","volume":"10","author":"AL Seidinger","year":"2015","unstructured":"Seidinger, A. L. et al. Occurrence of neuroblastoma among TP53 p.R337H carriers. PLoS ONE 10, 1\u201315 (2015).","journal-title":"PLoS ONE"},{"key":"73282_CR11","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1002\/cncr.30703","volume":"123","author":"MJ Mastellaro","year":"2017","unstructured":"Mastellaro, M. J. et al. Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: insights from the study of 55 families of children with adrenocortical tumors. Cancer 123, 3150\u20133158 (2017).","journal-title":"Cancer"},{"key":"73282_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1371\/journal.pone.0099893","volume":"9","author":"J Giacomazzi","year":"2014","unstructured":"Giacomazzi, J. et al. Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil. PLoS ONE 9, 6\u201312 (2014).","journal-title":"PLoS ONE"},{"key":"73282_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2005.12.039","volume":"245","author":"MIW Achatz","year":"2007","unstructured":"Achatz, M. I. W. et al. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett. 245, 96\u2013102 (2007).","journal-title":"Cancer Lett."},{"key":"73282_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1897-4287-10-3","volume":"10","author":"MCB Gomes","year":"2012","unstructured":"Gomes, M. C. B. et al. The R337H mutation in TP53 and breast cancer in Brazil. Hered. Cancer Clin. Pract. 10, 3 (2012).","journal-title":"Hered. Cancer Clin. Pract."},{"key":"73282_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1897-4287-12-8","volume":"12","author":"NM Cury","year":"2014","unstructured":"Cury, N. M., Ferraz, V. E. F. & Silva, W. A. TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families. Hered. Cancer Clin. Pract. 12, 1\u20138 (2014).","journal-title":"Hered. Cancer Clin. Pract."},{"key":"73282_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2350-15-55","volume":"15","author":"FC Silva","year":"2014","unstructured":"Silva, F. C. et al. Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients. BMC Med. Genet. 15, 1\u201311 (2014).","journal-title":"BMC Med. Genet."},{"key":"73282_CR17","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1001\/jamaoncol.2016.6389","volume":"3","author":"MNC da Formiga","year":"2017","unstructured":"da Formiga, M. N. C., De Andrade, K. C., Kowalski, L. P. & Achatz, M. I. Frequency of thyroid carcinoma in Brazilian TP53 p.R337H carriers with Li Fraumeni syndrome. JAMA Oncol. 3, 1400\u20131402 (2017).","journal-title":"JAMA Oncol."},{"key":"73282_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10689-017-0028-4","volume":"17","author":"GS Macedo","year":"2018","unstructured":"Macedo, G. S. et al. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers. Fam. Cancer 17, 269\u2013274 (2018).","journal-title":"Fam. Cancer"},{"key":"73282_CR19","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jsbmb.2019.04.011","volume":"190","author":"AM Ferreira","year":"2019","unstructured":"Ferreira, A. M. et al. Clinical spectrum of Li-Fraumeni syndrome\/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation. J. Steroid Biochem. Mol. Biol. 190, 250\u2013255 (2019).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"73282_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-13-187","volume":"13","author":"J Giacomazzi","year":"2013","unstructured":"Giacomazzi, J. et al. TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient. BMC Cancer 13, 1\u20138 (2013).","journal-title":"BMC Cancer"},{"key":"73282_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1590\/1678-4685-gmb-2014-0343","volume":"39","author":"KC Andrade","year":"2016","unstructured":"Andrade, K. C. et al. Early-onset breast cancer patients in the South and Southeast of Brazil should be tested for the TP53 p.R337H mutation. Genet. Mol. Biol. 39, 199\u2013202 (2016).","journal-title":"Genet. Mol. Biol."},{"key":"73282_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.canlet.2007.10.044","volume":"261","author":"EI Palmero","year":"2008","unstructured":"Palmero, E. I. et al. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett. 261, 21\u201325 (2008).","journal-title":"Cancer Lett."},{"key":"73282_CR23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1158\/1541-7786.MCR-09-0442","volume":"8","author":"JJ Jordan","year":"2010","unstructured":"Jordan, J. J. et al. Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. Mol. Cancer Res. 8, 701\u2013716 (2010).","journal-title":"Mol. Cancer Res."},{"key":"73282_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10689-015-9779-y","volume":"14","author":"M Fitarelli-Kiehl","year":"2015","unstructured":"Fitarelli-Kiehl, M. et al. The breast cancer immunophenotype of TP53-p.R337H carriers is different from that observed among other pathogenic TP53 mutation carriers. Fam. Cancer 14, 333\u2013336 (2015).","journal-title":"Fam. Cancer"},{"key":"73282_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370 (2000).","journal-title":"Cell"},{"key":"73282_CR26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"73282_CR27","doi-asserted-by":"publisher","first-page":"W460","DOI":"10.1093\/nar\/gkv403","volume":"43","author":"IS Vlachos","year":"2015","unstructured":"Vlachos, I. S. et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. 43, W460\u2013W466 (2015).","journal-title":"Nucleic Acids Res."},{"key":"73282_CR28","first-page":"D148","volume":"48","author":"HY Huang","year":"2020","unstructured":"Huang, H. Y. et al. miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Res. 48, D148\u2013D154 (2020).","journal-title":"Nucleic Acids Res."},{"key":"73282_CR29","first-page":"1116","volume":"84","author":"BC Figueiredo","year":"1999","unstructured":"Figueiredo, B. C. et al. Comparative genomic hybridization analysis of adrenocortical tumors of childhood 1. J. Clin. Endocrinol. Metab. 84, 1116\u20131121 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"73282_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms7302","volume":"6","author":"EM Pinto","year":"2015","unstructured":"Pinto, E. M. et al. Genomic landscape of paediatric adrenocortical tumours. Nat. Commun. 6, 1\u201310 (2015).","journal-title":"Nat. Commun."},{"key":"73282_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0165-4608(03)00123-7","volume":"146","author":"LR Cavalli","year":"2003","unstructured":"Cavalli, L. R. et al. Genetic and epigenetic alterations in sentinel lymph nodes metastatic lesions compared to their corresponding primary breast tumors. Cancer Genet. Cytogenet. 146, 33\u201340 (2003).","journal-title":"Cancer Genet. Cytogenet."},{"key":"73282_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000151311","volume":"122","author":"SCL Santos","year":"2008","unstructured":"Santos, S. C. L. et al. Patterns of DNA copy number changes in sentinel lymph node breast cancer metastases. Cytogenet. Genome Res. 122, 16\u201321 (2008).","journal-title":"Cytogenet. Genome Res."},{"key":"73282_CR33","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1073\/pnas.0307323101","volume":"101","author":"GA Calin","year":"2004","unstructured":"Calin, G. A. et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. 101, 2999\u20133004 (2004).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"73282_CR34","doi-asserted-by":"publisher","first-page":"9136","DOI":"10.1073\/pnas.0508889103","volume":"103","author":"L Zhang","year":"2006","unstructured":"Zhang, L. et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. 103, 9136\u20139141 (2006).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"73282_CR35","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1053\/j.seminoncol.2011.08.003","volume":"38","author":"D-A Landau","year":"2011","unstructured":"Landau, D.-A. & Slack, F. J. MicroRNAs in mutagenesis, genomic instability, and DNA repair. Semin. Oncol. 38, 743\u2013751 (2011).","journal-title":"Semin. Oncol."},{"key":"73282_CR36","doi-asserted-by":"publisher","first-page":"14475","DOI":"10.3390\/ijms150814475","volume":"15","author":"K Vincent","year":"2014","unstructured":"Vincent, K., Pichler, M., Lee, G. W. & Ling, H. MicroRNAs, genomic instability and cancer. Int. J. Mol. Sci. 15, 14475\u201314491 (2014).","journal-title":"Int. J. Mol. Sci."},{"key":"73282_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4331\/wjbc.v8.i1.45","volume":"8","author":"S Oliveto","year":"2017","unstructured":"Oliveto, S., Mancino, M., Manfrini, N. & Biffo, S. Role of microRNAs in translation regulation and cancer. World J. Biol. Chem. 8, 45 (2017).","journal-title":"World J. Biol. Chem."},{"key":"73282_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/294097","volume":"2012","author":"R Elston","year":"2012","unstructured":"Elston, R. & Inman, G. J. Crosstalk between p53 and TGF-\u03b2 Signalling. J. Signal Transduct. 2012, 1\u201310 (2012).","journal-title":"J. Signal Transduct."},{"key":"73282_CR39","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1038\/onc.2016.424","volume":"36","author":"WT Liu","year":"2017","unstructured":"Liu, W. T. et al. TGF-\u03b2 upregulates the translation of USP15 via the PI3K\/ AKT pathway to promote p53 stability. Oncogene 36, 2715\u20132723 (2017).","journal-title":"Oncogene"},{"key":"73282_CR40","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.3390\/ijms19071901","volume":"19","author":"HI Suzuki","year":"2018","unstructured":"Suzuki, H. I. MicroRNA control of TGF-\u03b2 signaling. Int. J. Mol. Sci. 19, 1901 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"73282_CR41","first-page":"1","volume":"5","author":"K Li","year":"2015","unstructured":"Li, K. et al. An integrated approach to reveal miRNAs\u2019 impacts on the functional consequence of copy number alterations in cancer. Sci. Rep. 5, 1\u201313 (2015).","journal-title":"Sci. Rep."},{"key":"73282_CR42","doi-asserted-by":"publisher","first-page":"79274","DOI":"10.18632\/oncotarget.13024","volume":"7","author":"B Sugita","year":"2016","unstructured":"Sugita, B. et al. Differentially expressed miRNAs in triple negative breast cancer between African-American and non-Hispanic white women. Oncotarget 7, 79274\u201379291 (2016).","journal-title":"Oncotarget"},{"key":"73282_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers10120475","volume":"10","author":"J Soh","year":"2018","unstructured":"Soh, J., Cho, H., Choi, C. H. & Lee, H. Identification and characterization of microRNAs associated with somatic copy number alterations in cancer. Cancers (Basel). 10, 1\u201318 (2018).","journal-title":"Cancers (Basel)."},{"key":"73282_CR44","doi-asserted-by":"publisher","first-page":"6184","DOI":"10.18632\/oncotarget.27250","volume":"10","author":"BM Sugita","year":"2019","unstructured":"Sugita, B. M. et al. Integrated copy number and miRNA expression analysis in triple negative breast cancer of Latin American patients. Oncotarget 10, 6184\u20136203 (2019).","journal-title":"Oncotarget"},{"key":"73282_CR45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2018.01.013","volume":"419","author":"Z Luo","year":"2018","unstructured":"Luo, Z., Cui, R., Tili, E. & Croce, C. Friend or foe: microRNAs in the p53 network. Cancer Lett. 419, 96\u2013102 (2018).","journal-title":"Cancer Lett."},{"key":"73282_CR46","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/cdd.2011.190","volume":"19","author":"S Donzelli","year":"2012","unstructured":"Donzelli, S. et al. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ. 19, 1038\u20131048 (2012).","journal-title":"Cell Death Differ."},{"key":"73282_CR47","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1038\/onc.2012.334","volume":"32","author":"P Dong","year":"2013","unstructured":"Dong, P. et al. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 32, 3286\u20133295 (2013).","journal-title":"Oncogene"},{"key":"73282_CR48","first-page":"1","volume":"4","author":"W Wang","year":"2013","unstructured":"Wang, W., Cheng, B., Miao, L., Me, Y. & Wu, M. Mutant p53\u2013R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression. Cell Death Dis. 4, 1\u201311 (2013).","journal-title":"Cell Death Dis."},{"key":"73282_CR49","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1038\/onc.2013.106","volume":"33","author":"S Masciarelli","year":"2014","unstructured":"Masciarelli, S. et al. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene 33, 1601\u20131608 (2014).","journal-title":"Oncogene"},{"key":"73282_CR50","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cancergen.2019.11.005","volume":"240","author":"I Cristina","year":"2020","unstructured":"Cristina, I. et al. MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p. (Arg337His) mutation carriers. Cancer Genet. 240, 54\u201358 (2020).","journal-title":"Cancer Genet."},{"key":"73282_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jrr\/rrz080","volume":"61","author":"A Matsui","year":"2020","unstructured":"Matsui, A. et al. Oxidation resistance 1 prevents genome instability through maintenance of G2\/M arrest in gamma-ray-irradiated cells. J. Radiat. Res. 61, 1\u201313 (2020).","journal-title":"J. Radiat. Res."},{"key":"73282_CR52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cancergencyto.2008.05.010","volume":"186","author":"R Rosati","year":"2008","unstructured":"Rosati, R. et al. High frequency of loss of heterozygosity at 11p15 and IGF2 overexpression are not related to clinical outcome in childhood adrenocortical tumors positive for the R337H TP53 mutation. Cancer Genet. Cytogenet. 186, 19\u201324 (2008).","journal-title":"Cancer Genet. Cytogenet."},{"key":"73282_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-7-101","volume":"7","author":"AG Silva","year":"2012","unstructured":"Silva, A. G., Achatz, I. M. W., Krepischi, A. C., Pearson, P. L. & Rosenberg, C. Number of rare germline CNVs and TP53 mutation types. Orphanet J. Rare Dis. 7, 1 (2012).","journal-title":"Orphanet J. Rare Dis."},{"key":"73282_CR54","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1210\/jc.2012-1184","volume":"97","author":"E Letouz\u00e9","year":"2012","unstructured":"Letouz\u00e9, E. et al. SNP array profiling of childhood adrenocortical tumors reveals distinct pathways of tumorigenesis and highlights candidate driver genes. J. Clin. Endocrinol. Metab. 97, 1284\u20131293 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"73282_CR55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1750-1172-9-63","volume":"9","author":"AG Silva","year":"2014","unstructured":"Silva, A. G. et al. The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations. Orphanet J. Rare Dis. 9, 2\u20137 (2014).","journal-title":"Orphanet J. Rare Dis."},{"key":"73282_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0035897","volume":"7","author":"E Letouz\u00e9","year":"2012","unstructured":"Letouz\u00e9, E. et al. Identity by descent mapping of founder mutations in cancer using high-resolution tumor SNP data. PLoS ONE 7, 1\u201311 (2012).","journal-title":"PLoS ONE"},{"key":"73282_CR57","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cancergen.2014.04.007","volume":"207","author":"C Torresan","year":"2014","unstructured":"Torresan, C. et al. Increased copy number of the DLX4 homeobox gene in breast axillary lymph node metastasis. Cancer Genet. 207, 177\u2013187 (2014).","journal-title":"Cancer Genet."},{"key":"73282_CR58","unstructured":"Bengtsson, H., Simpson, K., Bullard, J. & Hansen, K. aroma. affymetrix: a generic framework in R for analyzing small to very large Affymetrix data sets in bounded memory. Methods,Technical Report, 1\u20139 (2008)."},{"key":"73282_CR59","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1101\/gr.6861907","volume":"17","author":"K Wang","year":"2007","unstructured":"Wang, K. et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 17, 1665\u20131674 (2007).","journal-title":"Genome Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73282-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73282-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73282-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T20:30:30Z","timestamp":1670358630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73282-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73282"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73282-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"19 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16614"}}